MARKET

VBLT

VBLT

Vascular
NASDAQ
0.1553
-0.0013
-0.83%
After Hours: 0.1521 -0.0032 -2.06% 19:56 09/30 EDT
OPEN
0.1565
PREV CLOSE
0.1566
HIGH
0.1649
LOW
0.1545
VOLUME
714.11K
TURNOVER
0
52 WEEK HIGH
2.540
52 WEEK LOW
0.1452
MARKET CAP
10.77M
P/E (TTM)
-0.3298
1D
5D
1M
3M
1Y
5Y
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.
Zacks · 09/02 16:36
VBL Therapeutics Receives Non-Compliance Notice From Nasdaq
VBL Therapeutics Receives Non-Compliance Notice From Nasdaq
MT Newswires · 09/02 04:51
VBL Therapeutics receives non-compliance letter from Nasdaq
VBL Therapeutics (NASDAQ:VBLT) <a href="https://seekingalpha.com...
Seekingalpha · 09/01 21:27
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/15 21:35
VBL Therapeutics GAAP EPS of -$0.12
VBL Therapeutics press release (<span class="tic...
Seekingalpha · 08/15 20:58
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisorTEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immun...
GlobeNewswire · 08/15 20:05
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/08 14:00
Vascular Biogenics cuts 35% of workforce to save costs
Israeli biotech Vascular Biogenics (NASDAQ:VBLT) announce...
Seekingalpha · 08/02 12:35
More
About VBLT
Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Webull offers kinds of Vascular Biogenics Ltd stock information, including NASDAQ:VBLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VBLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VBLT stock methods without spending real money on the virtual paper trading platform.